Benefits of Policosanol

Evidence-Based Benefits

• LDL reduction (Cuban data) — Mas et al. (1999) reported LDL cholesterol reductions of 24% with 10mg policosanol daily and 30% at 20mg in multiple Cuban studies, though these results have been questioned.
• Anti-platelet activity — Arruzazabala et al. (1997) demonstrated that policosanol inhibits platelet aggregation in both in vitro and clinical studies, potentially through thromboxane/prostacyclin modulation.
• Antioxidant effects — policosanol has shown modest antioxidant capacity in preclinical studies, potentially reducing LDL oxidation, though clinical significance is uncertain.
• Safety profile — across all studies (Cuban and independent), policosanol consistently demonstrates excellent tolerability with very few adverse effects, making it among the safest supplements tested.

What the Research Says

Policosanol presents one of the most controversial evidence bases in supplement research. Numerous Cuban studies (Mas et al., 1999; Gouni-Berthold & Berthold, 2002) reported LDL reductions of 20-30%, but independent replication attempts have largely failed. Berthold et al. (2006) conducted a rigorous German RCT (n=143) using Cuban-sourced policosanol and found no significant effect on any lipid parameter, directly contradicting the Cuban findings. Greyling et al. (2006) in South Africa similarly found no cholesterol-lowering effect. The Cochrane Database notes that almost all positive studies originate from a single Cuban research group, raising concerns about publication bias or methodological issues. Policosanol remains safe but its efficacy for cholesterol management is not reliably established.

Related Conditions